Clinical Trial Update: A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eribulin in combination with HP neoadjuvant therapy for HER2-positive breast cancer (status: unknown).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Eribulin (eribulin mesilate)
• HP neoadjuvant therapy

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: HER2-positive Breast Cancer | Phase 2 | Status: UNKNOWN